Repeat measurements of glycated haemoglobin A 1c and N-terminal pro-B-type natriuretic peptide: Divergent behaviour in diabetes mellitus

European Journal of Clinical Investigation

Volumn 41, Issue 12, 2011, Pages 1292-1298

  Neuhold, Stephanie ^a   Resl, Michael ^a   Huelsmann, Martin ^a   Strunk, Guido ^b,c   Adlbrecht, Christopher ^a   Rath, Claus ^a   Prager, Rudolf ^d   Luger, Anton ^a   Clodi, Martin ^a   Pacher, Richard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Statistics   (Austria)

^c TU DORTMUND UNIVERSITY   (Germany)

^d Hietzing Hospital Vienna   (Austria)

Author keywords

Cardiovascular risk; Diabetes mellitus; Glycated haemoglobin A 1c; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN A1C;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; FEMALE; FOLLOW UP; GENDER; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORTALITY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REPEAT PROCEDURE;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 81355147750     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02539.x     Document Type: Article

References (30)

1. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-3.
2. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T et al. Plasma natriuretic peptide levels and risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
3. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P et al. Rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
4. Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006;49:2256-62.
5. Dawson A, Jeyaseelan S, Morris AD, Struthers AD. B-type natriuretic peptide as an alternative way of assessing total cardiovascular risk in patients with diabetes mellitus. Am J Cardiol 2005;96:933-4.
6. De Lemos Hildebrandt P. Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol 2008;101:16-20.
7. Huelsmann M, Neuhold S, Strunk G, Moertl D, Berger R, Prager R et al. NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 2008;29:2259-64.
8. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.
9. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
10. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
11. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
12. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
13. Brownlee M. The pathobiology of diabetic complications; a unifying mechanism. Diabetes 2005;54:1615-25.
14. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004;44:2293-300.
15. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.
16. Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS et al. Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes 2008;57:2445-52.
17. Nathan DM, Francis TB, Palmer JL. Effect of aspirin on determinations of glycosylated hemoglobin. Clin Chem 1983;29:466-9.
18. 1c levels in non-diabetic patients with end stage renal disease (ESRD) receiving hemodialysis. J Endocrinol Invest 2004;27:733-5.
19. 1c in nondiabetic patients. Acta Haematol 2004;112:126-8.
20. 1c levels. A cross-sectional analysis of 2 studies. Ann Intern Med 2010;152:770-7.
21. 1c levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins. Diabetes 2001;50:2858-63.
22. Hildebrandt P, Boesen M, Olsen M, Wachtell K, Groenning B. N-terminal pro brain natriuretic peptide in arterial hypertension-a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004;6:313-7.
23. DeFilippi C, van Kimmenade RR, Pinto YM. Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol 2008;101:82-8.
24. Mueller T, Dieplinger B, Poelz W, Endler G, Wagner G, Haltmayer M. Amino-terminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from Linz peripheral arterial disease study. Clin Chem 2009;55:68-77.
25. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
26. Huelsmann M, Neuhold S, Strunk G, Moertl D, Berger R, Pacher R et al. Comparison of BNP and NT-proBNP to predict outcome in chronic heart failure using different statistical models. European Heart Congress; Barcelona 2009; Abstract # 81032.
27. Gandhi GY, Murad HM, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB et al. Patient-important outcomes in registered diabetes trials. JAMA 2008;299:2543-9.
28. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:43-53.
29. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
30. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;385:2560-72.